News | February 18, 2022
AptarGroup reported 2021 sales at US $3.23 billion
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
TRIS AMINO HCl is widely used as a diagnostic reagent and as a downstream processing buffer in the purification of commercial biopharmaceuticals
Parkinson's disease treatment is the first and only carbidopa/levodopa (CD/LD) tablet designed to be divided for precise dosing
It will open new frontier for south-to-south collaboration and innovation transfer
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
The KRIVIDA Novus RT-PCR kit can detect the Omicron variant, its sub-lineages, and the Delta variant in 45 minutes
Expected to open later this year, the facility will significantly increase distribution capacity to meet the growing demand for production materials by Ireland's biopharma industry
It will showcase the company’s latest technologies in robotics, digital health and orthopaedic implants
Subscribe To Our Newsletter & Stay Updated
